Lund, Sweden – SmiLe is very pleased to announce the addition of Transient Pharma AB to our incubator program. Transient Pharma is dedicated to the development of innovative systemic anti-inflammatory treatments, focusing initially on gastrointestinal inflammatory disorders and curbing the excessive inflammation during acute infections.

 

Professor Artur Schmidtchen and CEO Helene Hartman

 

Transient Pharma´s groundbreaking research, originating from Professor Artur Schmidtchen’s lab at Lund University, has led to the development of TIM-03, a proprietary peptide with promising therapeutic potential. The peptide has demonstrated multifunctional properties consisting of strong anti-inflammatory effects (published in Nature Communications) and antimicrobial effects both in vitro and in vivo.

The mode of action is well understood, indicating that TIM-03 holds significant commercial potential for treating multiple inflammatory diseases, presenting a potentially broad pipeline opportunity.

”We are delighted to welcome yet another pharmaceutical development company to our incubator program. In addition, we are happy to have CEO Helene Hartman returning with a new company, a highly motivated leader who has already proven her capability in fostering the growth of startup companies and navigating the intricate landscape of drug development,” says Ulrika Ringdahl, COO of SmiLe Incubator.

The scientific article is published in Nature Communications (Petruk et al Nat Comm, 2023).

 

For more information, please contact:
Ulrika Ringdahl, COO at SmiLe
+46 (0)736-566232
ulrika.ringdahl@smileincubator.life

 

About SmiLe Venture Hub – Pioneering Life Science Innovations

SmiLe Incubator is a life science business incubator based in Medicon Village in Lund, Sweden. SmiLe offers business coaching, a broad international industry and investor network and a unique laboratory infrastructure with state-of-the art instrumentation. Since the start, SmiLe has helped 100+ entrepreneurs commercialize their business ideas. Currently there are some 30 companies in SmiLe incubator which, together with alumni companies, have attracted more than EUR 805 million in venture capital since 2014. To date, 21 of SmiLe´s companies have launched an IPO. SmiLe is a non-profit organization and receives basic funding from Region Skåne, Lund Municipality, Lund University and Medicon Village. SmiLe´s sponsors are Agilent, Sparbanken Skåne, Høiberg, Magle Chemoswed, Merck, Setterwalls, Zacco, Phase Holographic Imaging and ChemoMetec. www.smileincubator.life